A
Atalanta Therapeutics
Biotech & Life Sciences · Boston, United States · Founded 2018
Pioneering RNAi treatments for neurodegenerative diseases MoreLess
Atalanta Therapeutics is a pioneering biotechnology company specializing in RNA interference (RNAi) to develop groundbreaking gene silencing therapies. The company focuses on creating branched small interfering RNA (siRNA) molecules that can halt diseases at their genetic source. Atalanta's primary clients include pharmaceutical companies and research institutions seeking advanced therapeutic solutions for genetic disorders. Operating in the biopharmaceutical market, Atalanta employs a business model centered on research and development, clinical trials, and strategic partnerships. Revenue is generated through licensing agreements, research collaborations, and milestone payments from successful clinical advancements. The company's innovative approach leverages Nobel Prize-winning science to offer a powerful therapeutic strategy for treating a wide range of diseases.
Keywords: RNA interference, gene silencing, branched siRNA, biotechnology, genetic disorders, therapeutic solutions, clinical trials, pharmaceutical partnerships, research and development, biopharmaceutical market.
Company overview
Atalanta Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2018
- Headquarters
- Boston, United States
- Employees
- 39
- Open positions
- 1
- Dealroom signal
- 62.7
Valuation & funding
Atalanta Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jan 2025 | $97M | $388M | RiverVest Venture Partners · Pictet · F-Prime · GHR Foundation | ↗ |
| SERIES AOther financing | Jan 2021 | $110M | $440M | F-Prime | — |
| SPINOUTOther financing | Jan 2018 | $0 | — | University of Massachusetts Medical School | — |
Growth signals
Atalanta Therapeutics website traffic
Latest recorded traffic for Atalanta Therapeutics is 2.6K monthly website visits, down 23.5% over the last three months. Atalanta Therapeutics's team declined 32.8% over the past year.
Hiring
Open positions at Atalanta Therapeutics
Current openings linked to this company in Dealroom.
Comparisons
Atalanta Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Atalanta Therapeutics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Atalanta Therapeutics has talent and traffic
team presence
In the news
Latest news about Atalanta Therapeutics
Recent press, funding announcements, and product moves mentioning Atalanta Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Atalanta Therapeutics
An AI-synthesized read of the highest-engagement posts about Atalanta Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Atalanta Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.